Center for Scientific Review; Notice of Closed Meetings, 56430-56431 [2022-19870]

Download as PDF 56430 Federal Register / Vol. 87, No. 177 / Wednesday, September 14, 2022 / Notices Davis Drive, Durham, NC 27709 (Virtual Meeting). Contact Person: Varsha Shukla, Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, National Institute of Environmental Health Sciences, 530 Davis Drive, Keystone Building, Room 3094, Durham, NC 27713, 984–287–3288, Varsha.shukla@nih.gov. Name of Committee: Environmental Health Sciences Review Committee. Date: November 8–9, 2022. Time: 11 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Environmental Health Sciences, Keystone Building, 530 Davis Drive, Durham, NC 27709 (Virtual Meeting). Contact Person: Varsha Shukla, Scientific Review Officer, Scientific Review Branch, Division of Extramural Research and Training, National Institute of Environmental Health Sciences, 530 Davis Drive, Keystone Building, Room 3094 Durham, NC 27713, 984–287–3288, Varsha.shukla@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS.) Dated: September 9, 2022. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–19872 Filed 9–13–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings National Human Genome Research Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group Pathophysiology of Eye Disease—2 Study Section. Date: October 13–14, 2022. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites—Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015. Contact Person: Cibu Paul Thomas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1011–H, Bethesda, MD 20894, (301) 402–4341, thomascp@mail.nih.gov. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Dated: September 9, 2022. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–19884 Filed 9–13–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSKJM1Z7X2PROD with NOTICES Name of Committee: National Human Genome Research Institute Special Emphasis Panel; Genetic Counselors R25. Date: December 2, 2022. Time: 12:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute for Human Genome Research, National Institutes of Health, 6700B Rockledge Drive, Suite 300, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sarah Jo Wheelan, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute for Human Genome Research, National Institutes of Health, 6700B Rockledge Drive, Suite 300, Bethesda, MD 20892, (301) 435–1580, wheelansj@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) VerDate Sep<11>2014 18:31 Sep 13, 2022 Jkt 256001 PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 Group Aging Systems and Geriatrics Study Section. Date: October 13–14, 2022. Time: 9:30 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Roger Alan Bannister, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1010–D, Bethesda, MD 20892, (301) 435–1042, bannisterra@csr.nih.gov. Name of Committee: Risk, Prevention and Health Behavior Integrated Review Group Lifestyle Change and Behavioral Health Study Section. Date: October 13–14, 2022. Time: 10:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Pamela Jeter, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 10J08, Bethesda, MD 20892, (301) 827–6401, pamela.jeter@nih.gov. Name of Committee: Biology of Development and Aging Integrated Review Group Drug Discovery and Molecular Pharmacology Study Section. Date: October 17–18, 2022. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, 1 Bethesda Metro Center, Bethesda, MD 20814. Contact Person: Jeffrey Smiley, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6194, MSC 7804, Bethesda, MD 20892, 301–594– 7945, smileyja@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel Special Topics: Noninvasive Neuromodulation and Neuroimaging Technologies. Date: October 18–19, 2022. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Pablo Miguel Blazquez Gamez, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435–1042, pablo.blazquezgamez@nih.gov. Name of Committee: Molecular, Cellular and Developmental Neuroscience Integrated Review Group Neurodifferentiation, Plasticity, Regeneration and Rhythmicity Study Section. Date: October 19–20, 2022. Time: 9:00 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Alexandria Old Town, 1767 King Street, Alexandria, VA 22314. E:\FR\FM\14SEN1.SGM 14SEN1 56431 Federal Register / Vol. 87, No. 177 / Wednesday, September 14, 2022 / Notices Contact Person: Jacek Topczewski, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 1002A1, Bethesda, MD 20892, (301) 594–7574, topczewskij2@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: September 9, 2022. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–19870 Filed 9–13–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency Changes in Flood Hazard Determinations Federal Emergency Management Agency, Department of Homeland Security. ACTION: Notice. AGENCY: This notice lists communities where the addition or modification of Base Flood Elevations (BFEs), base flood depths, Special Flood Hazard Area (SFHA) boundaries or zone designations, or the regulatory floodway (hereinafter referred to as flood hazard determinations), as shown on the Flood Insurance Rate Maps (FIRMs), and where applicable, in the supporting Flood Insurance Study (FIS) reports, prepared by the Federal Emergency Management Agency (FEMA) for each community, is appropriate because of new scientific or technical data. The FIRM, and where applicable, portions of the FIS report, have been revised to reflect these flood hazard determinations through issuance of a Letter of Map Revision (LOMR), in SUMMARY: khammond on DSKJM1Z7X2PROD with NOTICES Arizona: Maricopa ........ Maricopa ........ VerDate Sep<11>2014 Location and case No. City of Glendale (21–09– 1877P). City of Goodyear (21–09– 1877P). 18:31 Sep 13, 2022 These flood hazard determinations will be finalized on the dates listed in the table below and revise the FIRM panels and FIS report in effect prior to this determination for the listed communities. From the date of the second publication of notification of these changes in a newspaper of local circulation, any person has 90 days in which to request through the community that the Deputy Associate Administrator for Insurance and Mitigation reconsider the changes. The flood hazard determination information may be changed during the 90-day period. DATES: The affected communities are listed in the table below. Revised flood hazard information for each community is available for inspection at both the online location and the respective community map repository address listed in the table below. Additionally, the current effective FIRM and FIS report for each community are accessible online through the FEMA Map Service Center at https:// msc.fema.gov for comparison. Submit comments and/or appeals to the Chief Executive Officer of the community as listed in the table below. FOR FURTHER INFORMATION CONTACT: Rick Sacbibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472, (202) 646–7659, or (email) patrick.sacbibit@fema.dhs.gov; or visit the FEMA Mapping and Insurance eXchange (FMIX) online at https:// www.floodmaps.fema.gov/fhm/fmx_ main.html. ADDRESSES: [Docket ID FEMA–2022–0002; Internal Agency Docket No. FEMA–B–2272] State and county accordance with Federal Regulations. The currently effective community number is shown in the table below and must be used for all new policies and renewals. The specific flood hazard determinations are not described for each community in this notice. However, the online location and local community map repository address where the flood SUPPLEMENTARY INFORMATION: hazard determination information is available for inspection is provided. Any request for reconsideration of flood hazard determinations must be submitted to the Chief Executive Officer of the community as listed in the table below. The modifications are made pursuant to section 201 of the Flood Disaster Protection Act of 1973, 42 U.S.C. 4105, and are in accordance with the National Flood Insurance Act of 1968, 42 U.S.C. 4001 et seq., and with 44 CFR part 65. The FIRM and FIS report are the basis of the floodplain management measures that the community is required either to adopt or to show evidence of having in effect in order to qualify or remain qualified for participation in the National Flood Insurance Program (NFIP). These flood hazard determinations, together with the floodplain management criteria required by 44 CFR 60.3, are the minimum that are required. They should not be construed to mean that the community must change any existing ordinances that are more stringent in their floodplain management requirements. The community may at any time enact stricter requirements of its own or pursuant to policies established by other Federal, State, or regional entities. The flood hazard determinations are in accordance with 44 CFR 65.4. The affected communities are listed in the following table. Flood hazard determination information for each community is available for inspection at both the online location and the respective community map repository address listed in the table below. Additionally, the current effective FIRM and FIS report for each community are accessible online through the FEMA Map Service Center at https:// msc.fema.gov for comparison. (Catalog of Federal Domestic Assistance No. 97.022, ‘‘Flood Insurance.’’) Michael M. Grimm, Assistant Administrator for Risk Management, Federal Emergency Management Agency, Department of Homeland Security. Chief executive officer of community Community map repository The Honorable Jerry Weiers, Mayor, City of Glendale, 5850 West Glendale Avenue, Suite 451, Glendale, AZ 85301. The Honorable Joe Pizzillo, Mayor, City of Goodyear, 190 North Litchfield Road, Goodyear, AZ 85338. City Hall, 5850 West Glendale Avenue, Glendale, AZ 85301. https://msc.fema.gov/portal/ advanceSearch. Nov. 18, 2022 .... 040045 Engineering and Development Services, 14455 West Van Buren Street, Suite D101, Goodyear, AZ 85338. https://msc.fema.gov/portal/ advanceSearch. Nov. 18, 2022 .... 040046 Jkt 256001 PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 Online location of letter of map revision E:\FR\FM\14SEN1.SGM 14SEN1 Date of modification Community No.

Agencies

[Federal Register Volume 87, Number 177 (Wednesday, September 14, 2022)]
[Notices]
[Pages 56430-56431]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-19870]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Brain Disorders and Clinical Neuroscience 
Integrated Review Group Pathophysiology of Eye Disease--2 Study 
Section.
    Date: October 13-14, 2022.
    Time: 9:00 a.m. to 7:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites--Chevy Chase Pavilion, 4300 Military Road 
NW, Washington, DC 20015.
    Contact Person: Cibu Paul Thomas, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 1011-H, Bethesda, MD 20894, (301) 
402-4341, [email protected].

    Name of Committee: Brain Disorders and Clinical Neuroscience 
Integrated Review Group Aging Systems and Geriatrics Study Section.
    Date: October 13-14, 2022.
    Time: 9:30 a.m. to 7:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, 
MD 20814.
    Contact Person: Roger Alan Bannister, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 1010-D, Bethesda, MD 20892, (301) 
435-1042, [email protected].

    Name of Committee: Risk, Prevention and Health Behavior 
Integrated Review Group Lifestyle Change and Behavioral Health Study 
Section.
    Date: October 13-14, 2022.
    Time: 10:00 a.m. to 8:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Pamela Jeter, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 10J08, Bethesda, MD 20892, (301) 827-6401, 
[email protected].

    Name of Committee: Biology of Development and Aging Integrated 
Review Group Drug Discovery and Molecular Pharmacology Study 
Section.
    Date: October 17-18, 2022.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, 1 Bethesda Metro Center, 
Bethesda, MD 20814.
    Contact Person: Jeffrey Smiley, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 6194, MSC 7804, Bethesda, MD 
20892, 301-594-7945, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel Special Topics: Noninvasive Neuromodulation and Neuroimaging 
Technologies.
    Date: October 18-19, 2022.
    Time: 9:00 a.m. to 7:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Rockledge II, 6701 
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Pablo Miguel Blazquez Gamez, Ph.D., Scientific 
Review Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 435-1042, 
[email protected].

    Name of Committee: Molecular, Cellular and Developmental 
Neuroscience Integrated Review Group Neurodifferentiation, 
Plasticity, Regeneration and Rhythmicity Study Section.
    Date: October 19-20, 2022.
    Time: 9:00 a.m. to 5:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Alexandria Old Town, 1767 King Street, Alexandria, 
VA 22314.

[[Page 56431]]

    Contact Person: Jacek Topczewski, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 1002A1, Bethesda, MD 20892, (301) 
594-7574, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: September 9, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-19870 Filed 9-13-22; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.